Cargando…

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) remains difficult to treat and urgently needs new therapeutic options. Nintedanib, a multikinase inhibitor, has exhibited efficacy in early clinical trials for HER2-negative breast cancer. In this study, we examined a new molecular mechanism of nintedanib in TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chun-Yu, Huang, Tzu-Ting, Chu, Pei-Yi, Huang, Chun-Teng, Lee, Chia-Han, Wang, Wan-Lun, Lau, Ka-Yi, Tsai, Wen-Chun, Chao, Tzu-I, Su, Jung-Chen, Chen, Ming-Huang, Shiau, Chung-Wai, Tseng, Ling-Ming, Chen, Kuen-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579508/ https://www.ncbi.nlm.nih.gov/pubmed/28798401 http://dx.doi.org/10.1038/emm.2017.114

Ejemplares similares

Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
por: Huang, Tzu-Ting, et al.
Publicado: (2017)

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma
por: Chen, Ji-Lin, et al.
Publicado: (2022)

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
por: Hu, Ming-Hung, et al.
Publicado: (2017)

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
por: Su, Jung-Chen, et al.
Publicado: (2016)

Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression
por: Huang, Tzu-Ting, et al.
Publicado: (2020)

Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2016)

Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2013)

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

CIP2A is a target of bortezomib in human triple negative breast cancer cells
por: Tseng, Ling-Ming, et al.
Publicado: (2012)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation
por: Chiu, Jen-Hwey, et al.
Publicado: (2020)

Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer
por: Huang, Yu-Hsiang, et al.
Publicado: (2021)

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2014)

Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib
por: Kunadu, Afua, et al.
Publicado: (2021)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression
por: Wang, Yao-Chen, et al.
Publicado: (2018)

Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review)
por: Chen, Yi-Li, et al.
Publicado: (2023)

Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis
por: Hong, Shiao-Ya, et al.
Publicado: (2023)

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer()()
por: Fan, Li-Ching, et al.
Publicado: (2015)

Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling
por: Tsai, Wan-Chen, et al.
Publicado: (2015)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
por: Su, Tung-Hung, et al.
Publicado: (2017)

Multidrug Resistance 1 Gene Variants, Pesticide Exposure, and Increased Risk of DNA Damage
por: Chen, Chun-Chieh, et al.
Publicado: (2014)

Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018)

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma
por: Huang, Chao-Yuan, et al.
Publicado: (2022)

Arylquin 1 (Potent Par-4 Secretagogue) Inhibits Tumor Progression and Induces Apoptosis in Colon Cancer Cells
por: Chen, Yi-Ting, et al.
Publicado: (2022)

Anchor-based classification and type-C inhibitors for tyrosine kinases
por: Hsu, Kai-Cheng, et al.
Publicado: (2015)

Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma
por: Hu, Zhongqian, et al.
Publicado: (2017)

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
por: Song, Zhendong, et al.
Publicado: (2021)

Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition
por: Hou, Duen-Ren, et al.
Publicado: (2013)

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2016)

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2017)

The role of tyrosine phosphatase Shp2 in spermatogonial differentiation and spermatocyte meiosis
por: Li, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u818fmvm9sdbeap2401cqjep3r